Indications of venetoclax/venetoclax

Venetoclax/Venetoclax is a targeted therapy drug with a wide range of indications.

1. Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Venexaclava is indicated for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma and has proven to be an effective treatment option. Both diseases are a common type of leukemia that affects the body's immune system, making patients susceptible to infections and leading to other serious health problems. Venetoclax interferes with the function of the B-cell lymphoma 2 (BCL-2) protein, prompting the patient's white blood cells to return to normal levels, thereby alleviating the condition.

2. Acute myeloid leukemia (AML): AML is a rapidly progressive type of leukemia that causes the bone marrow to produce abnormal white blood cells, thereby interfering with the normal hematopoietic process. Venetoclax is often used in combination with other drugs in this setting, particularly in adult patients aged 75 years and older and in those who cannot receive intensive induction chemotherapy. Combined application with drugs such as Azacitidine, Decitabine or low-dose Cytarabine can effectively inhibit the progression of AML and improve the survival rate of patients.

Overall, venetoclax has shown good efficacy and safety in the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma, as well as acute myeloid leukemia. However, for each patient, the treatment plan should be individualized based on their specific situation and the recommendations of their doctor to ensure the best possible treatment results.